Long-term follow-up from the phase 1/2a GDFATHER-01 trial reports deep and durable remissions by combining the GDF-15-neutralizing antibody visugromab with nivolumab in patients with immunotherapy-resistant advanced solid tumors. The results support a strategy aimed at overcoming resistance mechanisms associated with the GDF-15 axis. The study’s follow-up is positioned as clinically relevant because these patients represent a population that typically has limited options after anti–PD-1 failure or inadequate response. The durability element is key for whether such combinations become candidates for broader development. For drug developers, the paired antibody approach also adds to the growing catalog of resistance-targeting additions to standard checkpoint backbones—moving the focus from biomarker selection alone to directly blocking emerging tumor escape pathways.